Word

CAP-T

Status

Dead

Status Code

404

Status Date

Monday, May 11, 2020

Serial Number

79084150

Registration Number

4036922

Registration Date

Tuesday, October 11, 2011

Mark Type

4000

Filing Date

Tuesday, May 11, 2010

Published for Opposition

Tuesday, July 26, 2011

Cancellation Date

Monday, May 11, 2020

Trademark Owner History

CEVEC Pharmaceuticals GmbH - Original Registrant

Classifications

1 Chemical, biological and biochemical additives, preparations and reagents for use in the manufacture of chemicals, biologicals and biochemicals, namely, preparations and reagents for non medical use, in particular for scientific, research, laboratory, industrial and commercial purposes; chemical, biological and biochemical additives, preparations and reagents for research and characterisation of diseases for non-medical purposes; chemical, biological and biochemical additives, preparations and reagents, namely, cell lines, cells, proteins and polypeptides, for scientific and medical research and development of pharmaceuticals; chemical, biological and biochemical additives, preparations and reagents for use in the manufacture of medicines and pharmaceuticals; cultures of microorganisms other than for medical and veterinary use; cell lines, cells and amino acids for laboratory or research use; nucleic acid sequences, proteins and polypaptides for other than medical and veterinary use; diagnostic reagents and preparations comprising proteins, polypeptides, nucleotides, nucleic acids, cell lines and cells for scientific, research, laboratory, and commercial purposes for the development of medicines and for use in the manufacture of medicines and pharmaceuticals

5 Medicines, chemical, biological and biochemical preparations and proteins for the treatment of cancer, tumourous diseases, proliferative diseases, allergies, auto-immune diseases, inflammation, inflammatory diseases, infectious diseases, osteoporosis, graft versus host and host versus graft diseases, transplant rejection, coronary heart diseases, minimal residual diseases, restenosis, metabolic disorders, neurological disorders, diabetes, B cell malignancy, rheumatoid arthritis, immunological disorders, parasitic reactions, skin diseases, neurodegenerative diseases and cardiovascular diseases, except thyreostatica and cough and cold medicines; pharmaceutical and veterinary preparations and reagents for use in the treatment of cancer, tumorous diseases, proliferative diseases, allergies, auto-immune diseases, inflammation, inflammatory diseases, infectious diseases, osteoporosis, graft versus host and host versus graft diseases, transplant rejection, coronary heart diseases, minimal residual diseases, restenosis, metabolic disorders, neurological disorders, diabetes, B cell malignancy, rheumatoid arthritis, immunological disorders, parasitic reactions, skin diseases, neurodegenerative diseases and cardio-vascular diseases, except thyreostatica and cough and cold medicines; chemical, biological and biochemical reagents for medical and veterinary purposes, except thyreostatica and cough and cold medicines; diagnostic and analytic preparations for medical and veterinary purposes; cell lines, cells, diagnostic proteins and polypeptides for medical or clinical use; nucleic acid sequences, diagnostic proteins, polypeptides and chemical reagents for medical and veterinary purposes; amino acids for medical or veterinary purposes; diagnostic reagents and preparations, namely, microorganisms, proteins, polypeptides, nucleotides, nucleic acids, cell lines and cells for medical, veterinary and diagnostic purposes, except thyreostatica and cough and cold medicines

42 Scientific and industrial research, namely, in the fields of medicine, pharmaceuticals, molecular biology, biotechnology, immunology and genetics; research and development of medicines, diagnostic and analytic preparations, methods of therapy and expression systems; scientific and technological consulting services, namely, in the fields of medicine, pharmaceuticals, molecular biology, biotechnology, immunology and genetics; industrial consulting services, namely, consultancy pertaining to pharmacology; breeding, recovery, optimisation, synthesis and modification of cell culture lines, cells, microorganisms, polypeptides, proteins, nucleotides, nucleic acids for scientific, research, laboratory, industrial and commercial purposes, namely, for use in the fields of medicine, pharmaceuticals, molecular biology, biotechnology, immunology and genetics, for the development of medicines and for use in the manufacture of medicines and pharmaceuticals

Trademark Events

May 29, 2021

Notification Of Effect Of Cancellation Of Intl Reg Mailed

May 29, 2021

Death Of International Registration

Mar 15, 2019

Total Invalidation Processed By The Ib

Jan 28, 2019

Total Invalidation Of Reg Ext Protection Sent To Ib

Jan 28, 2019

Invalidation Processed

Jan 18, 2019

Total Invalidation Of Reg Ext Protection Created

May 18, 2018

Cancelled Section 71

Jun 11, 2012

Final Decision Transaction Processed By Ib

May 21, 2012

Final Disposition Notice Sent To Ib

May 21, 2012

Final Disposition Processed

Jan 11, 2012

Final Disposition Notice Created, To Be Sent To Ib

Nov 7, 2011

Limitation From The Ib Examined, No Action Is Needed

Oct 29, 2011

Limitation Of Goods Received From Ib

Oct 11, 2011

Registered-Principal Register

Jul 26, 2011

Official Gazette Publication Confirmation E-Mailed

Jul 26, 2011

Published For Opposition

Jun 20, 2011

Law Office Publication Review Completed

Jun 16, 2011

Assigned To Lie

Jun 9, 2011

Approved For Pub - Principal Register

Jun 9, 2011

Examiner's Amendment Entered

Jun 9, 2011

Notification Of Examiners Amendment E-Mailed

Jun 9, 2011

Examiners Amendment E-Mailed

Jun 9, 2011

Examiners Amendment -Written

Jun 7, 2011

Teas/Email Correspondence Entered

Jun 6, 2011

Correspondence Received In Law Office

Jun 6, 2011

Teas Request For Reconsideration Received

Feb 18, 2011

Notification Of Final Refusal Emailed

Feb 18, 2011

Final Refusal E-Mailed

Feb 18, 2011

Final Refusal Written

Feb 7, 2011

Teas/Email Correspondence Entered

Feb 7, 2011

Correspondence Received In Law Office

Feb 7, 2011

Teas Response To Office Action Received

Jan 21, 2011

Attorney/Dom.Rep.Revoked And/Or Appointed

Jan 21, 2011

Teas Revoke/App/Change Addr Of Atty/Dom Rep Received

Oct 5, 2010

Correction From The Ib Examined, No Action Is Needed

Sep 25, 2010

Refusal Processed By Ib

Sep 24, 2010

Correction Transaction Received From Ib

Aug 30, 2010

Non-Final Action Mailed - Refusal Sent To Ib

Aug 30, 2010

Refusal Processed By Mpu

Aug 27, 2010

Non-Final Action (Ib Refusal) Prepared For Review

Aug 26, 2010

Non-Final Action Written

Aug 19, 2010

Correction From The Ib Examined, No Action Is Needed

Aug 25, 2010

Correction From Ib Entered - Attorney Review Required

Aug 24, 2010

Assigned To Examiner

Aug 19, 2010

Correction Transaction Received From Ib

Jul 27, 2010

Application Filing Receipt Mailed

Jul 23, 2010

New Application Office Supplied Data Entered In Tram

Jul 22, 2010

Sn Assigned For Sect 66a Appl From Ib